Ionis Pharmaceuticals (IONS) Financial Analysis & Valuation | Quarter Chart
Ionis Pharmaceuticals (IONS)
IONSPrice: $80.69
Fair Value: 🔒
🔒score
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis... more
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. T... more
Description
Shares
| Market Cap | $13.34B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Brett Monia |
| IPO Date | 1991-05-17 | CAGR | 0.19% |
| Employees | 1,069 | Website | www.ionispharma.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
IONS chart loading...
Fundamentals
Technicals
| Enterprise Value | $15.10B | P/E Ratio | -46.91 |
| Forward P/E | -132.59 | PEG Ratio | — |
| P/S Ratio | 13.72 | P/B Ratio | 29.45 |
| P/CF Ratio | -15.9 | P/FCF Ratio | -14.95 |
| EPS | $-1.72 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | 47.49% | Gross Margin | 0.98% |
| Operating Margin | -0.33% | Profit Margin | -0.31% |
| ROE | -0.59% | ROA | -0.09% |
| ROCE | -0.13% | Current Ratio | 4.1 |
| Quick Ratio | 4.09 | Cash Ratio | 0.24 |
| Debt/Equity | 4.15 | Interest Coverage | -4.41 |
| Altman Z Score | 2.4 | Piotroski Score | 2 |